Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring

Talanta ◽  
2020 ◽  
Vol 208 ◽  
pp. 120450 ◽  
Author(s):  
Dora Koller ◽  
Viktoryia Vaitsekhovich ◽  
Cecile Mba ◽  
Juan L. Steegmann ◽  
Pablo Zubiaur ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Tyrosine Kinase ◽  
Human Plasma ◽  
Tyrosine Kinase Inhibitors ◽  
Drug Monitoring ◽  
Kinase Inhibitors ◽  
Therapeutic Drug

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

2014 ◽  
Vol 53 (4) ◽  
pp. 305-325 ◽  
Author(s):  
Huixin Yu ◽  
Neeltje Steeghs ◽  
Cynthia M. Nijenhuis ◽  
Jan H. M. Schellens ◽  
Jos H. Beijnen ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Drug Monitoring ◽  
Kinase Inhibitors ◽  
Therapeutic Drug ◽  
Practical Guidelines

scholarly journals Therapeutic drug monitoring and tyrosine kinase inhibitors

2016 ◽  
Vol 12 (2) ◽  
pp. 1223-1232 ◽  
Author(s):  
Pauline Herviou ◽  
Emilie Thivat ◽  
Damien Richard ◽  
Lucie Roche ◽  
Joyce Dohou ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Drug Monitoring ◽  
Kinase Inhibitors ◽  
Therapeutic Drug

scholarly journals Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Marwa Fouad ◽  
Maxime Helvenstein ◽  
Bertrand Blankert
Keyword(s):  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Tyrosine Kinase ◽  
Human Plasma ◽  
Tyrosine Kinase Inhibitors ◽  
High Performance ◽  
Kinase Inhibitors ◽  
Therapeutic Window ◽  
Therapeutic Drug

Generally, tyrosine kinase inhibitors have narrow therapeutic window and large interpatient variability compared to intrapatient variability. In order to support its therapeutic drug monitoring, two fast and accurate methods were developed for the determination of recently FDA approved anticancer tyrosine kinase inhibitors, afatinib and ibrutinib, in human plasma using ultra high performance liquid chromatography coupled to PDA detection. Diclofenac sodium was used as internal standard. The chromatographic separation was achieved on an Acquity UPLC BEH C18 analytical column using a mobile phase combining ammonium formate buffer and acetonitrile at a constant flow rate of 0.4 mL/min using gradient elution mode. AµSPE (solid phase extraction) procedure, using Oasis MCXµElution plates, was processed and it gave satisfying and reproducible results in terms of extraction yields. Additionally, the methods were successfully validated using the accuracy profiles approach (β= 95% and acceptance limits = ±15%) over the ranges 5–250 ng/mL for afatinib and from 5 to 400 ng/mL for ibrutinib in human plasma.

Sign in / Sign up

Export Citation Format

Share Document